Axitinib as a third or further line of treatment in renal cancer: a single institution experience.
Tsironis G, Liontos M, Kyriazoglou A, Koutsoukos K, Tsiara A, Kaparelou M, Zakopoulou R, Cohen A, Skafida E, Fontara S, Zagouri F, Bamias A, Dimopoulos MA.
Tsironis G, et al. Among authors: fontara s.
BMC Urol. 2020 Jun 2;20(1):60. doi: 10.1186/s12894-020-00618-1.
BMC Urol. 2020.
PMID: 32487200
Free PMC article.